There are several phase II clinical trials ongoing evaluating PD-L1 and other immune checkpoint inhibitors in high-grade and recurrent meningiomas, and this will hopefully shed light on the efficacy of these immunotherapies in meningioma. The gene discussed is CD274; the disease is meningioma.